Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Celecoxib in Metastatic Pancreatic Cancer
NCT00176813Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2003
- Primary completion
- Nov 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in pancreatic adenocarcinoma (PDAC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Overall Survival at 12 months. Started Mar 2003; status: completed.
02
Drugs
celecoxib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00176813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176813.